|
|
ReportsOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. In the least curable (ABC) subtype of DLBCL, survival of the malignant cells is dependent on constitutive activation of the nuclear factor–
1 Metabolism Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA B (NF-B) signaling pathway. In normal B cells, antigen receptor–induced NF-B activation requires CARD11, a cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumorigenesis, we sequenced the CARD11 gene in human DLBCL tumors. We detected missense mutations in 7 of 73 ABC DLBCL biopsies (9.6%), all within exons encoding the coiled-coil domain. Experimental introduction of CARD11 coiled-coil domain mutants into lymphoma cell lines resulted in constitutive NF-B activation and enhanced NF-B activity upon antigen receptor stimulation. These results demonstrate that CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
2 Amnis Corporation, Seattle, WA 98121, USA. 3 Biometric Research Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. 4 Department of Pathology, University of Würzburg, 97080 Würzburg, Germany. 5 Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany. 6 British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada. 7 Department of Pathology, University of Arizona, Tucson, AZ 85724, USA. 8 Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain. 9 Laboratory of Pathology, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. 10 Department of Immunology, Rikshospitalet-Radiumhospitalet Medical Center, N-0310 Oslo, Norway. 11 Institute for Cancer Research, Rikshospitalet University Hospital, N-0310 Oslo, Norway. 12 Centre for Cancer Biomedicine, Faculty Division, Norwegian Radium Hospital, University of Oslo, N-0310 Oslo, Norway. 13 Southwest Oncology Group, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA. 14 James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA. 15 Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA. * These authors contributed equally to this work.
The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
To whom correspondence should be addressed. E-mail: Science. ISSN 0036-8075 (print), 1095-9203 (online)
News | Science Journals | Careers | Blogs and Communities | Multimedia | Collections | Help | Site Map | RSS
Subscribe | Feedback | Privacy / Legal | About Us | Advertise With Us | Contact Us
© 2008 American Association for the Advancement of Science. All Rights Reserved.
AAAS is a partner of HINARI, AGORA, PatientInform, CrossRef, and COUNTER.
You have reached the bottom of the page. Back to top